Androgens in prostate cancer: A tale that never ends

被引：28

作者：

Hou, Zemin ^{[1
]}

Huang, Shengsong ^{[2
]}

Li, Zhenfei ^{[1
,2
]}

机构：

[1] Univ Chinese Acad Sci, Chinese Acad Sci, State Key Lab Cell Biol, CAS Ctr Excellence Mol Cell Sci,Shanghai Inst Bio, 320 Yueyang Rd, Shanghai 200031, Peoples R China

[2] Tongji Univ, Tongji Hosp, Dept Urol, Sch Med, Shanghai 200065, Peoples R China

来源：

CANCER LETTERS | 2021年 / 516卷

基金：

中国国家自然科学基金; 国家重点研发计划;

关键词：

Steroidogenesis; Abiraterone resistance; Enzalutamide resistance; Bipolar androgen therapy; Androgen receptor; HUMAN 3-BETA-HYDROXYSTEROID DEHYDROGENASE; DNA-BINDING DOMAIN; ABIRATERONE ACETATE; DEPRIVATION THERAPY; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CYTOCHROME B(5); DOUBLE-BLIND; CASTRATION; RECEPTOR;

D O I：

10.1016/j.canlet.2021.04.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the nextgeneration androgen receptor pathway inhibitors (ARPI), emphasize the function of the androgen-AR axis even in castration-resistant prostate cancer (CRPC). However, with the increased incidence in neuroendocrine prostate cancer (NEPC) showing resistance to ARPI, the importance of androgen-AR axis in further disease management remains elusive. Herein we review the steroidogenic pathways associated with different disease stages and discuss the potential targets for disease management after manifesting resistance to abiraterone and enzalutamide.

引用

页码：1 / 12

页数：12

共 138 条

[81] ERβ Impedes Prostate Cancer EMT by Destabilizing HIF-1α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading [J].

Mak, Paul ;

Leav, Irwin ;

Pursell, Bryan ;

Bae, Donggoo ;

Yang, Xiaofang ;

Taglienti, Cherie A. ;

Gouvin, Lindsey M. ;

Sharma, Vishva M. ;

Mercurio, Arthur M. .

CANCER CELL, 2010, 17 (04) :319-332

[82] DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer [J].

Mateo, J. ;

Carreira, S. ;

Sandhu, S. ;

Miranda, S. ;

Mossop, H. ;

Perez-Lopez, R. ;

Rodrigues, D. Nava ;

Robinson, D. ;

Omlin, A. ;

Tunariu, N. ;

Boysen, G. ;

Porta, N. ;

Flohr, P. ;

Gillman, A. ;

Figueiredo, I. ;

Paulding, C. ;

Seed, G. ;

Jain, S. ;

Ralph, C. ;

Protheroe, A. ;

Hussain, S. ;

Jones, R. ;

Elliott, T. ;

McGovern, U. ;

Bianchini, D. ;

Goodall, J. ;

Zafeiriou, Z. ;

Williamson, C. T. ;

Ferraldeschi, R. ;

Riisnaes, R. ;

Ebbs, B. ;

Fowler, G. ;

Roda, D. ;

Yuan, W. ;

Wu, Y. -M. ;

Cao, X. ;

Brough, R. ;

Pemberton, H. ;

A'Hern, R. ;

Swain, A. ;

Kunju, L. P. ;

Eeles, R. ;

Attard, G. ;

Lord, C. J. ;

Ashworth, A. ;

Rubin, M. A. ;

Knudsen, K. E. ;

Feng, F. Y. ;

Chinnaiyan, A. M. ;

Hall, E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (18) :1697-1708

[83] Identification of a principal mRNA species for human 3α-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity [J].

Matsuura, K ;

Shiraishi, H ;

Hara, A ;

Sato, K ;

Deyashiki, Y ;

Ninomiya, M ;

Sakai, S .

JOURNAL OF BIOCHEMISTRY, 1998, 124 (05) :940-946

[84] The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders [J].

Miller, Walter L. ;

Auchus, Richard J. .

ENDOCRINE REVIEWS, 2011, 32 (01) :81-151

[85] Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions [J].

Mohammad, Osama S. ;

Nyquist, Michael D. ;

Schweizer, Michael T. ;

Balk, Stephen P. ;

Corey, Eva ;

Plymate, Stephen ;

Nelson, Peter S. ;

Mostaghel, Elahe A. .

CANCERS, 2017, 9 (12)

[86] Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth [J].

Montgomery, R. Bruce ;

Mostaghel, Elahe A. ;

Vessella, Robert ;

Hess, David L. ;

Kalhorn, Thomas F. ;

Higano, Celestia S. ;

True, Lawrence D. ;

Nelson, Peter S. .

CANCER RESEARCH, 2008, 68 (11) :4447-4454

[87] Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer [J].

Mostaghel, Elahe A. ;

Zhang, Ailin ;

Hernandez, Susana ;

Marck, Brett T. ;

Zhang, Xiaotun ;

Tamae, Daniel ;

Biehl, Heather E. ;

Tretiakova, Maria ;

Bartlett, Jon ;

Burns, John ;

Dumpit, Ruth ;

Ang, Lisa ;

Matsumoto, Alvin M. ;

Penning, Trevor M. ;

Balk, Steven P. ;

Morrissey, Colm ;

Corey, Eva ;

True, Lawrence D. ;

Nelson, Peter S. .

CLINICAL CANCER RESEARCH, 2019, 25 (01) :426-439

[88] Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants [J].

Mostaghel, Elahe A. ;

Marck, Brett T. ;

Plymate, Stephen R. ;

Vessella, Robert L. ;

Balk, Stephen ;

Matsumoto, Alvin M. ;

Nelson, Peter S. ;

Montgomery, R. Bruce .

CLINICAL CANCER RESEARCH, 2011, 17 (18) :5913-5925

[89] Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy [J].

Narayanan, Sujata ;

Srinivas, Sandy ;

Feldman, David .

NATURE REVIEWS UROLOGY, 2016, 13 (01) :47-60

[90] The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer [J].

Nishiyama, T ;

Hashimoto, Y ;

Takahashi, K .

CLINICAL CANCER RESEARCH, 2004, 10 (21) :7121-7126

← 4 5 6 7 8 9 10 11 12 13 →